- Report
- February 2024
- 110 Pages
Global
From €4592EUR$4,750USD£3,945GBP
- Report
- November 2023
- 180 Pages
Global
From €4737EUR$4,900USD£4,069GBP
- Report
- January 2022
- 200 Pages
Global
From €7251EUR$7,500USD£6,228GBP
- Report
- May 2020
- 482 Pages
Global
From €9185EUR$9,500USD£7,889GBP
- Drug Pipelines
- August 2018
- 37 Pages
Global
From €9668EUR$10,000USD£8,304GBP
- Report
- August 2018
- 18 Pages
Global
From €9668EUR$10,000USD£8,304GBP
- Report
- August 2018
- 19 Pages
Global
From €9668EUR$10,000USD£8,304GBP
- Report
- January 2024
- 89 Pages
Global
From €3500EUR$3,878USD£3,112GBP
- Report
- February 2024
- 198 Pages
Global
From €3480EUR$3,600USD£2,990GBP
- Report
- September 2019
Global
From €5192EUR$5,370USD£4,459GBP
Dacomitinib is a type of lung cancer drug used to treat non-small cell lung cancer (NSCLC). It is a tyrosine kinase inhibitor (TKI) that works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. Dacomitinib is used in combination with other drugs to treat NSCLC that has spread to other parts of the body or that has not responded to other treatments. It is also used to treat NSCLC that has a certain type of genetic mutation. Common side effects of dacomitinib include fatigue, nausea, diarrhea, and rash.
Several companies are involved in the dacomitinib market, including Pfizer, AstraZeneca, and Novartis. These companies are involved in the research, development, and marketing of dacomitinib and other lung cancer drugs. Show Less Read more
